Canterbury DHB

Context

Thiopurine Dosing Guideline in Immunosuppressive Therapy

1 in 200 individuals (0.5%) have severe TPMT deficiency which results in rapid life-threatening myelosuppression, usually within 7 to 10 days of initiating treatment.

In This Section

Definitions

Thiopurine Methyltransferase (TPMT)

Other Monitoring

6-TGN and 6-MMP Monitoring

Definitions

Thiopurine Methyltransferase (TPMT)

Other Monitoring

6-TGN and 6-MMP Monitoring

Information about this Canterbury DHB document (191833):

Document Owner:

Not assigned (see Who's Who)

Last Updated:

October 2020 (Thiopurine Dosing Guideline in Immunosuppressive Therapy)

Next Review Due:

October 2023

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document.

Topic Code: 191833